Guilin Sanjin(SZ:002275)2025-06-13 08:30Group 1: Sales and Marketing Strategy - The company maintains a strict control over sales expenses, with a focus on precision and targeted investment in sales efforts [1] - Sales expense rates for first-line products are relatively low, while investment is shifting towards second and third-line products based on market dynamics [1] - The overall sales expense rate is expected to remain stable throughout the year, aligning with sales revenue [1] Group 2: Inventory Management - The company has upgraded its inventory management system, utilizing a BI intelligent analysis system to enhance efficiency [1] - A scientific "finished goods inventory standard model" has been established to balance market demand dynamics and cost control [1] - The overall inventory level has significantly decreased compared to previous years, maintaining a healthy inventory cycle of 1.5 to 2 months [1] Group 3: Product Growth Potential - The growth trend for second and third-line products is positive, with continued support from the company [2] - The sales of the product "Gaqi Dingtuan Capsule" are expected to maintain last year's growth rate, while the "Dizziness Ning" series has surpassed 100 million in sales in 2021 [2] - Other products like "Shu Yan Qing Spray" and "Compound Cold Medicine Granules" are also expected to achieve high growth rates [2] Group 4: Dividend Policy - The company is committed to providing stable returns to investors and has consistently implemented a cash dividend policy since its listing [2] - For the 2024 annual equity distribution plan, the company proposes a cash dividend of 3.5 yuan per 10 shares, totaling 206 million yuan [2] - The dividend policy is expected to remain unchanged unless there are special funding needs [2]